China's Biocytogen gets $78m Series D

Existing investors CMB International – an investment arm of China Merchants Bank – Materia Medica Capital, and 3E Bioventures also participated in the funding round, according to a release. All three participated, along with SDIC, in Biocytogen’s RMB410 million Series C round last year.

Biocytogen specializes in supplying drug testing facilities with genetically engineered mice for experimentation. It uses genetic engineering to reduce the occurrence of random mutations that could affect the reliability of testing results, giving its mice an advantage over traditionally bred laboratory animals. In addition, its gene editing technique has been used to create mice with human-like systems to provide scientists with more accurate results.

The company was founded in 2009 and has facilities in Boston, Shanghai, and Haimen, in addition to its headquarters in Beijing. Its clients include major global pharmaceutical companies such as Merck, Takeda, EMD, and Sanofi. Biocytogen will use the new capital for market development, service upgrading, and product development, with a specific focus on animals for immunology research.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Greater China
• Healthcare
• Expansion
• China
• China Life
• SDIC Fund Management
• Growth capital